Which therapy works better in choroid plexus carcinomas?

Su G. Berrak, Diane D. Liu, Brigitte Wrede, Johannes E. Wolff

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Choroid plexus carcinomas (CPCs) are rare tumors with dismal outcome. While it has been established that surgery, radiotherapy, and chemotherapy improve survival, the best chemotherapy drugs for treating this disease still need to be identified. Since CPC is too rare to permit a prospective clinical trial, we performed a metaanalysis to evaluate the effects of individual drugs in patients with CPCs. We expanded a pre-existing database and included all cases of choroid plexus tumors, identified in PubMed through the end of 2007, for a total of 906 patients. At first, we restricted the analysis to patients with histologically confirmed CPC (n = 361) and with residual tumor after surgery (n = 130/361 patients), and we compared response and survival between patients who received a particular drug and those who did not. Response to chemotherapy was documented in 43 patients. Of the drugs used in these patients, etoposide was associated with the highest response rate (17/36). Next survival was compared among all CPC. Kaplan-Meier curves and log-rank tests suggested a statistically significant treatment benefit for cyclophosphamide, etoposide, and carboplatin, while the effect of vincristine was found to be marginally significant (P = 0.07, log rank). Of these, only etoposide's effect could be confirmed in a limited Cox multiple regression analysis. In conclusion, etoposide should be included in future standard treatment protocols. However the survival rates are still unsatisfactory, and additional novel drugs should be studied in prospective multicenter studies.

Original languageEnglish (US)
Pages (from-to)155-162
Number of pages8
JournalJournal of Neuro-Oncology
Volume103
Issue number1
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Etoposide
Pharmaceutical Preparations
Drug Therapy
Therapeutics
Survival
Choroid Plexus Neoplasms
Carboplatin
Residual Neoplasm
Vincristine
Clinical Protocols
Choroid Plexus Carcinoma
PubMed
Cyclophosphamide
Multicenter Studies
Radiotherapy
Survival Rate
Regression Analysis
Clinical Trials
Databases
Prospective Studies

Keywords

  • Chemotherapy
  • Choroid plexus tumors
  • Etoposide
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Which therapy works better in choroid plexus carcinomas? / Berrak, Su G.; Liu, Diane D.; Wrede, Brigitte; Wolff, Johannes E.

In: Journal of Neuro-Oncology, Vol. 103, No. 1, 05.2011, p. 155-162.

Research output: Contribution to journalArticle

Berrak, SG, Liu, DD, Wrede, B & Wolff, JE 2011, 'Which therapy works better in choroid plexus carcinomas?', Journal of Neuro-Oncology, vol. 103, no. 1, pp. 155-162. https://doi.org/10.1007/s11060-010-0372-9
Berrak, Su G. ; Liu, Diane D. ; Wrede, Brigitte ; Wolff, Johannes E. / Which therapy works better in choroid plexus carcinomas?. In: Journal of Neuro-Oncology. 2011 ; Vol. 103, No. 1. pp. 155-162.
@article{b5f95652c20e4a32b4b616e5e60708b5,
title = "Which therapy works better in choroid plexus carcinomas?",
abstract = "Choroid plexus carcinomas (CPCs) are rare tumors with dismal outcome. While it has been established that surgery, radiotherapy, and chemotherapy improve survival, the best chemotherapy drugs for treating this disease still need to be identified. Since CPC is too rare to permit a prospective clinical trial, we performed a metaanalysis to evaluate the effects of individual drugs in patients with CPCs. We expanded a pre-existing database and included all cases of choroid plexus tumors, identified in PubMed through the end of 2007, for a total of 906 patients. At first, we restricted the analysis to patients with histologically confirmed CPC (n = 361) and with residual tumor after surgery (n = 130/361 patients), and we compared response and survival between patients who received a particular drug and those who did not. Response to chemotherapy was documented in 43 patients. Of the drugs used in these patients, etoposide was associated with the highest response rate (17/36). Next survival was compared among all CPC. Kaplan-Meier curves and log-rank tests suggested a statistically significant treatment benefit for cyclophosphamide, etoposide, and carboplatin, while the effect of vincristine was found to be marginally significant (P = 0.07, log rank). Of these, only etoposide's effect could be confirmed in a limited Cox multiple regression analysis. In conclusion, etoposide should be included in future standard treatment protocols. However the survival rates are still unsatisfactory, and additional novel drugs should be studied in prospective multicenter studies.",
keywords = "Chemotherapy, Choroid plexus tumors, Etoposide, Treatment",
author = "Berrak, {Su G.} and Liu, {Diane D.} and Brigitte Wrede and Wolff, {Johannes E.}",
year = "2011",
month = "5",
doi = "10.1007/s11060-010-0372-9",
language = "English (US)",
volume = "103",
pages = "155--162",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Which therapy works better in choroid plexus carcinomas?

AU - Berrak, Su G.

AU - Liu, Diane D.

AU - Wrede, Brigitte

AU - Wolff, Johannes E.

PY - 2011/5

Y1 - 2011/5

N2 - Choroid plexus carcinomas (CPCs) are rare tumors with dismal outcome. While it has been established that surgery, radiotherapy, and chemotherapy improve survival, the best chemotherapy drugs for treating this disease still need to be identified. Since CPC is too rare to permit a prospective clinical trial, we performed a metaanalysis to evaluate the effects of individual drugs in patients with CPCs. We expanded a pre-existing database and included all cases of choroid plexus tumors, identified in PubMed through the end of 2007, for a total of 906 patients. At first, we restricted the analysis to patients with histologically confirmed CPC (n = 361) and with residual tumor after surgery (n = 130/361 patients), and we compared response and survival between patients who received a particular drug and those who did not. Response to chemotherapy was documented in 43 patients. Of the drugs used in these patients, etoposide was associated with the highest response rate (17/36). Next survival was compared among all CPC. Kaplan-Meier curves and log-rank tests suggested a statistically significant treatment benefit for cyclophosphamide, etoposide, and carboplatin, while the effect of vincristine was found to be marginally significant (P = 0.07, log rank). Of these, only etoposide's effect could be confirmed in a limited Cox multiple regression analysis. In conclusion, etoposide should be included in future standard treatment protocols. However the survival rates are still unsatisfactory, and additional novel drugs should be studied in prospective multicenter studies.

AB - Choroid plexus carcinomas (CPCs) are rare tumors with dismal outcome. While it has been established that surgery, radiotherapy, and chemotherapy improve survival, the best chemotherapy drugs for treating this disease still need to be identified. Since CPC is too rare to permit a prospective clinical trial, we performed a metaanalysis to evaluate the effects of individual drugs in patients with CPCs. We expanded a pre-existing database and included all cases of choroid plexus tumors, identified in PubMed through the end of 2007, for a total of 906 patients. At first, we restricted the analysis to patients with histologically confirmed CPC (n = 361) and with residual tumor after surgery (n = 130/361 patients), and we compared response and survival between patients who received a particular drug and those who did not. Response to chemotherapy was documented in 43 patients. Of the drugs used in these patients, etoposide was associated with the highest response rate (17/36). Next survival was compared among all CPC. Kaplan-Meier curves and log-rank tests suggested a statistically significant treatment benefit for cyclophosphamide, etoposide, and carboplatin, while the effect of vincristine was found to be marginally significant (P = 0.07, log rank). Of these, only etoposide's effect could be confirmed in a limited Cox multiple regression analysis. In conclusion, etoposide should be included in future standard treatment protocols. However the survival rates are still unsatisfactory, and additional novel drugs should be studied in prospective multicenter studies.

KW - Chemotherapy

KW - Choroid plexus tumors

KW - Etoposide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79959971011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959971011&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0372-9

DO - 10.1007/s11060-010-0372-9

M3 - Article

C2 - 20976614

AN - SCOPUS:79959971011

VL - 103

SP - 155

EP - 162

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -